Dr. Reddy's Laboratories Limited — Board Meeting, 05-11-2024: Outcome of Board Meeting

Dr. Reddy's Laboratories reported Q2 and H1 FY25 financial results, with consolidated revenues of ₹80,162 million (up 17% YoY) and ₹156,889 million (up 15% YoY), respectively. Notable investments include ₹600 Crores into Dr. Reddy's Laboratories LLC, Russia, for working capital. The company also completed the acquisition of Haleon’s Nicotine Replacement Therapy portfolio for ₹51,407 million and operationalized its partnership with Nestle for nutraceutical products. Profit after tax attributable to equity holders decreased by 15% YoY for Q2.